Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakomy, David S., Urbauer, Diana L., Westin, Shannon N., Lin, Lilie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974697/
https://www.ncbi.nlm.nih.gov/pubmed/31993510
http://dx.doi.org/10.1016/j.ctro.2019.12.005
_version_ 1783490148062724096
author Lakomy, David S.
Urbauer, Diana L.
Westin, Shannon N.
Lin, Lilie L.
author_facet Lakomy, David S.
Urbauer, Diana L.
Westin, Shannon N.
Lin, Lilie L.
author_sort Lakomy, David S.
collection PubMed
description PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers.
format Online
Article
Text
id pubmed-6974697
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69746972020-01-28 Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers Lakomy, David S. Urbauer, Diana L. Westin, Shannon N. Lin, Lilie L. Clin Transl Radiat Oncol Article PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers. Elsevier 2019-12-28 /pmc/articles/PMC6974697/ /pubmed/31993510 http://dx.doi.org/10.1016/j.ctro.2019.12.005 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Lakomy, David S.
Urbauer, Diana L.
Westin, Shannon N.
Lin, Lilie L.
Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
title Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
title_full Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
title_fullStr Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
title_full_unstemmed Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
title_short Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
title_sort phase i study of the parp inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974697/
https://www.ncbi.nlm.nih.gov/pubmed/31993510
http://dx.doi.org/10.1016/j.ctro.2019.12.005
work_keys_str_mv AT lakomydavids phaseistudyoftheparpinhibitortalazoparibwithradiationtherapyforlocallyrecurrentgynecologiccancers
AT urbauerdianal phaseistudyoftheparpinhibitortalazoparibwithradiationtherapyforlocallyrecurrentgynecologiccancers
AT westinshannonn phaseistudyoftheparpinhibitortalazoparibwithradiationtherapyforlocallyrecurrentgynecologiccancers
AT linliliel phaseistudyoftheparpinhibitortalazoparibwithradiationtherapyforlocallyrecurrentgynecologiccancers

Ejemplares similares